Clinical trials: Urinary System Tumor
Carcinoma, Carcinoma Renal Cell
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research.
- Conditions
- Carcinoma, Carcinoma Renal Cell, Kidney Neoplasms, Kidney Diseases
- Trial name
- ChemoRenCan (NCT01339975)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 310 people
- Sponsor
- University Hospital, Bordeaux
Renal Cancer Metastatic
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
- Trial name
- NCT05215470
- Testing
- Nivolumab, Ipilimumab
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
NMIBC
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are…
- Trial name
- NCT06810141
- Testing
- rMBCG
- Where
- 66 sites in United States
- Sponsor
- ImmunityBio, Inc.
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has…
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT00942331
- Testing
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 873 sites in United States, Puerto Rico
- Volunteers
- 506 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Renal Cancer
HPI Effect in Robotic Urological Surgery on AKI
It is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after robot-assisted urological surgery.
- Conditions
- Prostate Cancer, Renal Cancer, Urologic Diseases
- Trial name
- NCT06051162
- Testing
- BP management with HPI guidance
- Where
- South Korea
- Volunteers
- 124 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Non-Muscle Invasive Bladder Cancer (NMIBC)
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- NCT04179162
- Testing
- Bacillus Calmette-Guérin (BCG), Gemcitabine
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urologic Diseases, Urologic Cancer
Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies
The project aims to collect fresh biological material derived both from surgical resections performed in diseases, neoplastic and otherwise, of urological relevance at the level of the prostate, bladder, kidney, testicle and…
- Conditions
- Urologic Diseases, Urologic Cancer, Infertility
- Trial name
- NCT06187870
- Testing
- Collection of biological data
- Where
- Italy
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Kidney Cancer
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer.
- Trial name
- NCT00014183
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Bladder Cancer
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
Background: Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treating it.
- Trial name
- NCT03327883
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma
Study of Nivolumab for Advanced Cancers in India
This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Kidney Cancer
- Trial name
- NCT03444766
- Testing
- Nivolumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary…
- Trial name
- NCT03945162
- Testing
- Ruvidar® (TLD-1433) bladder infusion and PDT
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Theralase® Technologies Inc.
Cancer of Kidney, Kidney Cancer
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
- Conditions
- Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney
- Trial name
- NCT00199888
- Testing
- 124-Iodine-cG250 (124I-cG250)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ludwig Institute for Cancer Research
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Drug Screening Using Novel IMD in Renal Cell Carcinoma
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of…
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
- Trial name
- NCT05700461
- Testing
- Implantable Microdevice (IMD)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Oliver Jonas
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as…
- Conditions
- Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High
- Trial name
- MITRIC (NCT05286294)
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Advanced Kidney Cancer, Kidney Cancer
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose…
- Conditions
- Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03308396
- Testing
- Guadecitabine, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Ajjai Alva, MD
Carcinoma, Renal Cell
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT04626479
- Testing
- Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 393 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney…
- Trial name
- NCT00403169
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Renal Cell Carcinoma
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the…
- Trial name
- INTerpath-004 (NCT06307431)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 63 sites in United States, Argentina and 12 more
- Volunteers
- 272 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer, Prostate Tumor
Comparison of Two Insertion Technique of I-gel
To evaluate the efficacy of rotational technique in the insertion of i-gel
- Conditions
- Prostate Cancer, Prostate Tumor, Bladder Cancer, Bladder Tumor
- Trial name
- I-gel90 (NCT01826565)
- Testing
- Rotational technique
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.